Thirty five patients with the advanced epithelial ovarian cancer were treated with VP-16 plus cisplatin(VPP). The treatment consists of VP-16(100 mg/㎡, IV, day 1~3) and cisplatin (20 mg/㎡, IV, day 1~5) every 3 weeks. Five patients were
inevaluable for
response because they were lost to follow up after the first course of treatment. Of the 30 evaluable patients. 21 (70%) patients had been previously treated with other chemotherapy regimen. Ten patients achieved complete responses(33%) and five
patients achieved partial responses(17%), giving an overall response rate of 50%. The median disease-free interval for the complete responders and the median response duration for all responders were 10.5 months(the range; 1~27+) and 16
months(the
range: 3~32+), respectively. Overall survival time ranged from 2 months to 45+ months with a median value of 25 months. The main hematologic toxicities were the leukopenia(39%) and anemia(48%), and non-hematologic aide effects included nausea,
vomiting,
alopecia, and peripheral neuropathy. These toxicities were observed commonly, but most of those were of mild degree and easily manageable.
In conclusion, VPP combination chemotherapy is an effective treatment regimen for the advanced epithelial ovarian cancer.
|